Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery

References

• Akiyama Y, Nagahara N, Kashihara T, Hirai S, Toguchi H. In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly(acrylic acid) derivative. Pharm Res 1995; 12: 397–405
   PubMed Web of Science ®Google Scholar
• Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994; 11: 1358–1361
   PubMed Web of Science ®Google Scholar
• Asherman J, Stevenson M, Brownson E, Katre NV. Depofoam™ technology: A vehicle for controlled delivery of protein and peptide drugs. J Control Release 2000; 64: 155–166
   PubMed Web of Science ®Google Scholar
• Bangham AD, Standish NM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238–252
   PubMed Web of Science ®Google Scholar
• Callens C, Remon JP. Evaluation of starch-maltodextrin-Carbopol 974 P mixtures for the nasal delivery of insulin in rabbits. J Control Release 2000; 66: 215–220
   PubMed Web of Science ®Google Scholar
• Chalasani KB, Russell-Jones GJ, Yandrapu SK, Diwan PV, Jain SK. A novel vitamin B12—nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release 2007a; 117: 421–429
   PubMed Web of Science ®Google Scholar
• Chalasani KB, Russell-Jones GJ, Jain AK, Diwan PV, Jain SK. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release 2007b, (Article in press)
   Web of Science ®Google Scholar
• Chetty DJ, Chien YW. Novel methods of insulin delivery: An update. Crit Rev Ther Drug Carrier Syst 1998; 15: 629–670
   PubMed Web of Science ®Google Scholar
• Coates PA, Ismail IS, Luzio SD, Griffiths I, Ollerton RL, Volund A, Owens DR. Intranasal insulin: The effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects. Diabet Med 1995; 12: 235–239
   PubMed Web of Science ®Google Scholar
• Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1997; 1331: 187–211
   PubMed Web of Science ®Google Scholar
• Damge C, Vranckx H, Balschmidt P, Couvreur P. Poly (alkyl cyanoacrylate) nanospheres for oral administration of insulin. J Pharm Sci 1997; 86: 1403–1409
   PubMed Web of Science ®Google Scholar
• Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of endocrine pancreas. Goodman & Gilman's the pharmacological basis of therapeutics9th ed., JG Hardman, LE Limbird, PB Molinoff, RW Ruddeon, AG Gilman. McGraw-Hill, New York 1996; 1487–1517
   Google Scholar
• Drejer K, Vaag A, Bech K, Hansen P, Sorensen AR, Mygind N. Intranasal administration of insulin with phospholipid as absorption enhancer: Pharmacokinetics in normal subjects. Diabet Med 1992; 9: 335–340
   PubMed Web of Science ®Google Scholar
• Durrani AM, Farr SJ, Kellaway IW. Precorneal clearance of mucoadhesive microspheres from the rabbit eye. J Pharm Pharmacol 1995; 47: 581–584
   PubMed Web of Science ®Google Scholar
• Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 1999; 16: 1576–1581
   PubMed Web of Science ®Google Scholar
• Frauman AG, Jerums G, Louis WJ. Effects of intranasal insulin in non-obese type II diabetics. Diabetes Res Clin Pract 1987; 3: 197–202
   PubMed Web of Science ®Google Scholar
• Haffejee N, DuPlessis J, Muller DG, Schultz C, Kotze AF, Goosen C. Intranasal toxicity of selected absorption enhancers. Pharmazie 2001; 56: 882–888
   PubMed Web of Science ®Google Scholar
• Hilsted J, Madsbad S, Hvidberg A, Rasmussen MH, Krarup T, Ipsen H, Hansen B, Pedersen M, Djurup R, Oxenboll B. Intranasal insulin therapy: The clinical realities. Diabetologia 1995; 38: 680–684
   PubMed Web of Science ®Google Scholar
• Hinchcliffe M, Illum L. Intranasal insulin delivery and therapy. Adv Drug Deliv Rev 1999; 35: 199–234
   PubMed Web of Science ®Google Scholar
• Illum L, Daviss SS. Intranasal insulin: Clinical pharmacokinetics. Clin Pharmacokinet 1992; 23: 30–41
   PubMed Web of Science ®Google Scholar
• Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 1994; 11: 1186–1189
   PubMed Web of Science ®Google Scholar
• Jacobs MA, Schreuder RH, Jap-A-Joe K, Nauta JJ, Andersen PM, Heine RJ. The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers. Diabetes 1993; 42: 1649–1655
   PubMed Web of Science ®Google Scholar
• Kahn CR, Shechter Y. Insulin, oral hypoglycemic agents, and the pharmacology of endocrine pancreas. Goodman & Gilman's the pharmacological basis of therapeutics9th ed., JG Hardman, LE Limbird, PB Molinoff, RW Ruddeon, AG Gilman. McGraw-Hill, New York 1990; 1463–1495
   Google Scholar
• Katre NV. Lipid based multivesicular carriers for sustained delivery of therapeutic proteins and peptides. BioPharm Lab 2001; 8–11
   Google Scholar
• Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y. Mucoadhesive dl-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm Dev Technol 2000; 5: 77–85
   PubMed Web of Science ®Google Scholar
• Kim S, Turker MS, Chi EY, Sela S, Martin GM. Preparation of multivesicular liposomes. Biochim Biophys Acta 1983; 728: 339–348
   PubMed Web of Science ®Google Scholar
• Lee YC, Simamora P, Yalkowsky SH. Systemic delivery of insulin via an enhancer-free ocular device. J Pharm Sci 1997; 86: 1361–1364
   PubMed Web of Science ®Google Scholar
• Mastrandrea LD, Quattrin T. Clinical evaluation of inhaled insulin. Adv Drug Deliv Rev 2006; 58: 1061–1075
   PubMed Web of Science ®Google Scholar
• Morgan RV, Huntzicker MA. Delivery of systemic regular insulin via the ocular route in dogs. J Ocul Pharmacol 1996; 12: 515–526
   Google Scholar
• Novo Nordisk A/S, Denmark. 1991. Diabetes research—improving quality of life, Press release, Novo Nordisk, Corporate PR and Press Relations, Washington, DC, June 26
   Google Scholar
• Prego C, Garcia M, Torres D, Alonso MJ. Transmucosal macromolecular drug delivery. J Control Release 2005; 101: 151–162
   PubMed Web of Science ®Google Scholar
• Sanchez A, Ygartua P, Fos D. Role of surfactants in the bioavailability of intranasal insulin. Eur J Drug Metab Pharmacokinet 1991; 3: 120–124
   Google Scholar
• Sasaki H, Tei C, Yamamura K, Nishida K, Nakamura J. Effect of preservatives on systemic delivery of insulin by ocular instillation in rabbits. J Pharm Pharmacol 1994; 46: 871–875
   PubMed Web of Science ®Google Scholar
• Schipper NG, Olsson S, Hoogstraate JA, deBoer AG, Varum KM, Artursson P. Chitosan as absorption enhancers for poorly absorbable drugs 2: Mechanism of absorption enhancement. Pharm Res 1997; 14: 923–929
   PubMed Web of Science ®Google Scholar
• Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand RA. Efficacy of inhaled human insulin in type 1 diabetes mellitus: A randomised proof-of-concept study. Lancet 2001; 357: 331–335
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. Mucoadhesion of polymer-coated liposomes to rat intestine in vitro. Chem Pharm Bull 1994; 42: 1954–1956
   PubMed Web of Science ®Google Scholar
• Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm Res 1996; 13: 896–901
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Luo AM, Dodda-Kashi S, Lee VHL. The ocular route for systemic insulin delivery in the albino rabbit. J Pharmacol Exp Ther 1989; 249: 249–255
   PubMed Web of Science ®Google Scholar